Welcome to Cabometyx.eu website. This website is intended for EU Healthcare professionals only.
Please confirm below that you are a registered healthcare professional.
Two pivotal trials were conducted to provide clinical data to support the use of CABOMETYX®(cabozantinib) in advanced renal cell carcinoma (RCC).
In the pivotal, phase II, CABOSUN study, the efficacy and safety of cabozantinib was compared with sunitinib in the first-line treatment of RCC.1, 7, 8
In the pivotal, phase III, METEOR study, the efficacy and safety of cabozantinib following prior vascular endothelial growth factor (VEGF)-targeted therapy was compared with everolimus in treatment for RCC.1, 9–11